

Barry E Storer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7930544/publications.pdf>

Version: 2024-02-01

40
papers

6,062
citations

201385

27
h-index

360668

35
g-index

40
all docs

40
docs citations

40
times ranked

6666
citing authors

#	ARTICLE	IF	CITATIONS
1	Carfilzomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Pilot Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 278-284.	2.0	10
2	Disability Related to Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 772-777.	2.0	16
3	Early Mixed Lymphoid Donor/Host Chimerism is Associated with Improved Transplant Outcome in Patients with Primary or Secondary Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2197-2203.	2.0	12
4	Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen mismatched donors. <i>Blood</i> , 2020, 136, 1499-1506.	0.6	16
5	Ixazomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1612-1619.	2.0	12
6	Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e409-e418.	2.2	84
7	Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 956-963.	2.0	18
8	Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 386-392.	2.0	52
9	Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 555-562.	2.0	50
10	An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2017, 130, 360-367.	0.6	52
11	Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1257-1263.	2.0	29
12	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 10-23.	2.0	20
13	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. <i>Blood</i> , 2016, 128, 2350-2358.	0.6	43
14	Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw042.	3.0	170
15	Biomarker Panel for Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2016, 34, 2583-2590.	0.8	118
16	Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. <i>Blood</i> , 2015, 126, 113-120.	0.6	110
17	Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. <i>Blood</i> , 2014, 124, 1363-1371.	0.6	86
18	Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 549-555.	2.0	47

#	ARTICLE	IF	CITATIONS
19	Treosulfan-Based Conditioning and Hematopoietic Cell Transplantation for Nonmalignant Diseases: A Prospective Multicenter Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1996-2003.	2.0	51
20	Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 3249-3256.	0.8	361
21	Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 1530-1538.	0.8	197
22	Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. <i>Blood</i> , 2013, 121, 2340-2346.	0.6	55
23	Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study. <i>Haematologica</i> , 2012, 97, 451-458.	1.7	77
24	Clinical Benefit of Response in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1517-1524.	2.0	47
25	Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose. <i>Blood</i> , 2012, 120, 354-354.	0.6	0
26	Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 124-132.	2.0	26
27	Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2011, 118, 456-463.	0.6	75
28	Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I-Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients with Hematologic Malignancies: A Multicenter Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 384-394.	2.0	39
29	Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2009, 113, 5074-5082.	0.6	143
30	Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. <i>Blood</i> , 2009, 114, 702-708.	0.6	218
31	Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Blood</i> , 2007, 110, 2744-2748.	0.6	156
32	Duration of immunosuppressive treatment for chronic graft-versus-host disease. <i>Blood</i> , 2004, 104, 3501-3506.	0.6	269
33	Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. <i>Blood</i> , 2003, 101, 1620-1629.	0.6	424
34	Hematopoietic Stem-Cell Transplantation for Treatment-Related Leukemia or Myelodysplasia. <i>Journal of Clinical Oncology</i> , 2001, 19, 2134-2141.	0.8	79
35	Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, 18, 695-706.		2,407
36	Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, 18, 695.		8

#	ARTICLE	IF	CITATIONS
37	Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, 18, 695.		22
38	Transplantation of Marrow Cells From Unrelated Donors for Treatment of High-Risk Acute Leukemia: The Effect of Leukemic Burden, Donor HLA-Matching, and Marrow Cell Dose. Blood, 1997, 89, 4226-4235.	0.6	358
39	A Diagnostic for Cox Regression and General Conditional Likelihoods. Journal of the American Statistical Association, 1985, 80, 139-147.	1.8	81
40	A Diagnostic for Cox Regression and General Conditional Likelihoods. , 0, .		24